ESMO23
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
ESMO23
Dec 31, 2023, 20:07 |
Blog
Katsuaki Maehara: Patritumab Deruxtecan (HER3-DXd) clinical trial transition
Katsuaki Maehara, Director of Medical Education Colleagues, recently shared a post by EGFR Resisters on X/Twitter,…
Dec 19, 2023, 10:00 |
Blog
Amanda Nizam on biomarkers of TRAEs associated with EV for advanced urothelial carcinoma - GU Oncology Now
Amanda Nizam, a Genitourinary Medical Oncologist at Cleveland Clinic, recently shared a post by GU…
Dec 17, 2023, 17:21 |
Insight
SABCS23 Day 3 Highlights by Oncology Brothers
Oncology Brothers have recently shared their highlights from SABCS23. Below we feature the third day's…
Dec 17, 2023, 03:29 |
Blog
Advancing the Battle Against Platinum-Resistant Ovarian Cancer: Promising Strategies from 2023 ASCO & ESMO Meetings
The 2023 ASCO and ESMO meetings provided novel insights for treating platinum-resistant ovarian cancer, a…
Dec 5, 2023, 19:22 |
Blog
Amy C. Moore: Chris Conneran's energy and passion is infectious!
Amy C. Moore, VP, Global Engagement and Patient Partnerships at LUNGevity Foundation, shared the following…
Nov 4, 2023, 00:33 |
Blog
Hripsime-Gina Martirosyan: Advocating for cancer care in Armenia: how it works in a resource-limited country
Hripsime-Gina Martirosyan, Founding CEO, Patient advocate at HENARAN charitable foundation, shared a post by HENARAN…
Nov 2, 2023, 01:12 |
Blog
Cristian Massacesi: I never fail to be impressed by my teams’ commitment in delivering science
Cristian Massacesi, Chief Medical Officer & Oncology Chief Development Officer at AstraZeneca, made the following…
Nov 1, 2023, 14:40 |
Societies
Sarah Louden: ESMO23 USA in Florida
Sarah Louden, Founder and CEO of Total Health, stated the following on LinkedIn: ''What an…
Oct 31, 2023, 09:39 |
Insight
Paolo A. Ascierto: The history of melanoma is changing!
Paolo A. Ascierto, Director Department of Melanoma/Skin Cancers, Cancer Immunotherapy and Development Therapeutics at IRCCS,…
Oct 29, 2023, 17:37 |
Opinion
Mark Lanasa: The data we presented at ESMO are only the beginning of our story in solid tumors
Mark Lanasa, Chief Medical Officer of Solid Tumors at BeiGene, shared on LinkedIn: "I had…
Oct 29, 2023, 17:07 |
Blog
David Fredrickson: When it comes to driving breakthroughs in cancer care, curiosity is a superpower
David Fredrickson, Executive Vice-President of Oncology Business at AstraZeneca, shared a post on LinkedIn: "When…
Oct 29, 2023, 03:34 |
Drugs
Steven O'Day: The research we shared underscores BOT’s broad potential utility across multiple advanced solid tumors
Steven O'Day, the Chief Medical Officer of Agenus, shared on LinkedIn: "It was an exciting…
Oct 28, 2023, 01:34 |
Blog
Herbert Loong reflects on ESMO23
Herbert Loong, Clinical Associate Professor at The Chinese University of Hong Kong, recently posted on…
Oct 27, 2023, 04:33 |
Blog
We were honoured to receive an award from our Community 365 contributors, ECO Foundation - European Cancer Organisation
European Cancer Organisation shared on LinkedIn: "This weekend, we were honoured to receive an award…
Oct 27, 2023, 04:23 |
Insight
The first randomised trial of a targeted agent versus immunotherapy plus chemotherapy in a biomarker-selected patient population - CUHK Medicine
CUHK Medicine shared on LinkedIn: " More than doubled lung cancer patients’ progression-free survival Lung…
Oct 26, 2023, 18:23 |
Blog
Ainhoa Madariaga: Happy to present at ESMO23 the results of MBOT the first app
Ainhoa Madariaga, Medical Oncologist at 12 Octubre University Hospital, shared on X/Twitter: "Happy to present…
Oct 26, 2023, 09:27 |
Opinion
Maurizio Scaltriti: What stands out at ESMO23 is the critical role that innovative trial design, early mechanistic studies and ongoing translational analysis play in informing treatment strategy
Oct 25, 2023, 19:02 |
Insight
Amalya Sargsyan: ESMO23 - Advances in EGFR mutated NSCLC
Amalya Sargsyan, Research Fellow at Immune Oncology Research Institute, shared a post on LinkedIn: "ESMO23:…
Oct 25, 2023, 18:50 |
Blog
Emre Yekedüz: Our results including more than 20,000 patients were presented as a poster at ESMO23
Quoting Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University, on X/Twitter: ''Our results…
Oct 25, 2023, 18:13 |
Blog
Aradhana Sarin: Science + Finance = Innovation
Quoting Aradhana Sarin, Group CFO and Executive Director of AstraZeneca, on LinkedIn: ''Science + Finance =…
Oct 25, 2023, 17:27 |
Insight
Tom Powles: TAR-210 releases Erdafitinib slowly into the bladder by a novel release system
Tom Powles, Director of Barts Cancer Centre, shared on Twitter: ''Something NEW. TAR-210 releases Erdafitinib…
Oct 24, 2023, 20:07 |
Blog
Svetlana Nikic: When we think about innovations in precision oncology, who wins? Commercial drivers or clinical unmet need?
Svetlana Nikic, Founder of Precision Oncology Consulting, made the following post on LinkedIn: "Very interesting…
Oct 24, 2023, 16:16 |
Blog
Caroline Markham: Coming to ESMO23 is about meeting new societies and strengthening relationships with existing partners
Caroline Markham, Head of Strategic Partnerships at Touch Medical Media Services Ltd., shared on her LinkedIn…
Oct 24, 2023, 14:57 |
Blog
ESMO updates from Presidential Symposium- European Society for Medical Oncology (ESMO)
European Society for Medical Oncology (ESMO) shared on LinkedIn: "Positive outcomes in advanced or metastatic…
Oct 24, 2023, 13:49 |
Opinion
Flavia Jacobs: At ESMO23 we presented the results of our systematic review and meta-analysis evaluating PFS by central vs. local assessment in randomized clinical trials in metastatic breast cancer
Oct 23, 2023, 22:57 |
Blog
Thanking ESMO23 Social Media Ambassadors for their enthusiastic reporting from the Congress - The European Society for Medical Oncology
The European Society for Medical Oncology, made the following post on Twitter: "Thanking ESMO23 Social…
Oct 23, 2023, 17:21 |
Blog
Tara Frenkl: Navigating the complexities of life after a prostate cancer diagnosis goes beyond the physical
Tara Franklin, Head of Oncology Department at Bayer, shared on LinkedIn: “Navigating the complexities of…
Oct 23, 2023, 13:26 |
Insight
Marcelo Corassa: Great presentation by the amazing Jarushka Naidoo on the promises and pitfalls of neoadjuvant therapy for NSCLC
Marcelo Corassa, Medical oncologist and Clinical Researcher at Beneficência Portuguesa de São Paulo, shared on…
Oct 23, 2023, 13:15 |
Drugs
Pashtoon Kasi: We should drop the modified nomenclature and just agree on just dosing schema for FOLFIRINOX
Quoting Pashtoon Kasi, Oncologist and Researcher at Weill Cornell Medicine, on X/Twitter: ''ESMO23 Moving forward…
Oct 22, 2023, 17:42 |
Blog
Jerry Ndumbalo: Advancement in Oncology, Honoring excellence, and Global impact at ESMO 2023
Jerry Ndumbalo, President of Tanzania Oncology Society(TOS), shared on LinkedIn: "ESMO 2023: Advancement in Oncology,…
Oct 22, 2023, 17:36 |
Blog
What is the current status of real-world evidence (RWE) in oncology? - ESMO
ESMO (European Society for Medical Oncology) shared on LinkedIn: "What is the current status of…
Oct 22, 2023, 17:28 |
Career
Susana Banerjee: Honoured to receive fellow ESMO (FESMO) award ESMO2023
Susana Banerjee, Professor in Women's Cancers at The Institute of Cancer Research, shared on X/Twitter:…
Oct 21, 2023, 19:37 |
Blog
Amol Akhade: Do we need to study every new IO drug against Pembrolizumab plus chemo in first line NSCLC? NO.
Amol Akhade, Senior Consultant in Medical and Hematooncology at the Dr Hitendra Patil's Suyog Cancer…
Oct 21, 2023, 19:37 |
Blog
Jose Fernando Moura: Phase 2 PERLA trial shows a new option in same setting NSCLC 1st line.
Jose Fernando Moura, Oncologist and Principal Investigator in Solid Tumors at Real Hospital Portuguese and…
Oct 21, 2023, 19:36 |
Blog
Nicola Fusco: It has been a genuine pleasure to visit the Institute Gustave Roussy
Nicola Fusco shared a post on LinkedIn: “It has been a genuine pleasure to visit…
Oct 21, 2023, 19:24 |
Opinion
Olubukola Ayodele: Day 1 of ESMO 2023 was all about early breast cancer (EBC) for me today
Olubukola Ayodele, Consultant Medical Oncologist at University Hospitals of Leicester NHS trust, shared on LinkedIn:…
Oct 21, 2023, 19:13 |
Career
Melvin LK Chua: What a lecture East meets West by Prof Anthony Chan
Melvin LK Chua, Head of Department of Head Neck and Toracic Cancers, Division of Radiation…
Oct 20, 2023, 20:02 |
Insight
10 ESMO23 breast cancer abstracts not to miss by Paolo Tarantino
Paolo Tarantino, Research Fellow at the Dana-Farber Cancer Institute, shared on Twitter: "ESMO23 will have…
Oct 17, 2023, 01:31 |
Blog
Sharlene Gill: ESMO23 is less than a week away... See u in Madrid!
Sharlene Gill, President of the Canadian Association of Medical Oncologists, shared on Twitter: "ESMO23 is…
Oct 8, 2023, 18:02 |
Blog
Lillian Siu: Many exciting presentations on Developmental Therapeutics ESMO23.
Lillian Siu shared on X/Twitter: "Many exciting presentations on Developmental Therapeutics ESMO23 - New ADCs, novel…
Oct 8, 2023, 17:42 |
Insight
Rahul Gosain: Less than 3 weeks to ESMO23, here is a list of key abstracts for general oncology that could change our SoC!
Quoting Rahul Gosain, Medical Director and Director of Regional Infusion Services at the Wilmot Cancer…
Aug 6, 2023, 17:11 |
Blog
Here’s a personal, non-exhaustive selection of highly awaited phase 3 trials that may shape practice within the next year - Paolo Tarantino
With ESMO23 and SABCS23 approaching, we may soon see the results from several potentially practice-changing…
All:
42
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube